Novel targeted therapies for R/R CLL, including venetoclax plus rituximab, acalabrutinib, and zanubrutinib, have favorable safety profiles. Bendamustine plus rituximab showed a lower risk of severe ...

The American Society of Hematology (ASH) released guidelines on frontline management of acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs), as well as the management of relapsed ...

Sofi-cel, an allogeneic CAR-T therapy, targets CD7 and uses CRISPR/Cas9 to prevent fratricide and reduce graft-versus-host disease risk. The FDA's breakthrough therapy designation facilitates ...

ORLANDO, Fla. — Adding epcoritamab (Epkinly) to the standard-of-care (SOC) therapy of lenalidomide (Revlimid) and rituximab (Rituxan), a combination known as R 2, lowered the risk for disease ...

Please provide your email address to receive an email when new articles are posted on . The treatment is approved for heavily pretreated patients. Researchers reported an objective response rate of 70 ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved revumenib for patients aged 1 year and older with relapsed or refractory acute myeloid leukemia ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this 12-part journey through a disease state ...

Monjuvi in combination with lenalidomide and rituximab significantly improved PFS in patients with relapsed/refractory follicular lymphoma. The Food and Drug Administration (FDA) has approved Monjuvi ...

Among the efficacy evaluable patients, 42% achieved complete remission within 3 months. The Food and Drug Administration (FDA) has approved Aucatzyl ® (obecabtagene autoleucel; obe-cel) for the ...

Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma Eligible ...